Medicover
Medcover Q2: Stronger than expected (Redeye)

2020-07-24 14:37
Redeye maintains its valuation of Medicover after today's Q2 report. Medicover has proven resilient, the crisis has been temporary and management has navigated well through the many challenges. While we maintain our base case of SEK 127 per share, we raise our bull case to SEK 150. We see the current price levels as a good opportunity for investors looking for steady and resilient growth to build up a position.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Medicover B - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -